WORLDWIDE APPROVAL

TRIUMEQ Tablets

Algeria
Argentina
Armenia
Aruba
Australia
Bahrain
Botswana
Brazil
Canada
Chile
Colombia
Costa Rica
Curacao
Dominican Republic
Ecuador
European Union
Guyana
Hong Kong
Israel
Jamaica
Japan
Kenya
Lebanon
Macau
Macedonia
Namibia
Oman
Pakistan
Panama
Peru
Qatar
Republic of Korea
Saudi Arabia
Serbia
Singapore
South Africa
Switzerland
Taiwan
Trinidad and Tobago
Turkey
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States of America
Uruguay

- ✓ "**Approval" means: Marketing Authorisation has been granted by a country or there is no formal regulatory process in place, in the relevant country.**
- ✓ **Granted Marketing Authorisations may include limitations on the use of the product.**

This document was prepared on 08 March 2026 and will be updated on a quarterly basis by ViiV Healthcare. It is made available for information purposes only and ViiV Healthcare accepts no liability arising from the reliance by third parties, on the information provided.